Opinion

Video

Optimizing ALK-TKI Sequencing and Neurological Outcomes

Author(s):

Balazs Halmos, MD,Julia Rotow, MD

Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.

  1. For patients already on different first-line treatment, under what circumstances would you consider switching them to lorlatinib?
  2. How should we approach CNS surveillance and management in ALK-positive patients?
Related Videos
Related Content